News

PDL BioPharma Announces Fourth Quarter and Year End 2016 Financial Results

INCLINE VILLAGE, Nev., March 1, 2017 /PRNewswire/ — PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today
reported financial results for the fourth quarter and year ended December 31, 2016 including:Š

  • Total revenues of $66.5 million and $244.3 million for the three and twelve months ended December 31, 2016,
    respectively.
  • GAAP diluted EPS of ($0.06) and $0.39 for the three and twelve months ended December 31, 2016, respectively.
  • GAAP net loss attributable to PDL’s shareholders of $10.3 million and net income of $63.6 million for the three and
    twelve months ended December 31, 2016, respectively.
  • Non-GAAP net loss attributable to PDL’s shareholders of $8.6 million and net income of $108.1 million for the three
    and twelve months ended December 31, 2016, respectively. A full reconciliation of all components of the GAAP to
    non-GAAP financial results can be found in Table 4 at the end of the release.

Read Full Text

Leave a Reply

Your email address will not be published. Required fields are marked *